EMA — authorised 26 March 2021
- Marketing authorisation holder: ARVELLE THERAPEUTICS NETHERLANDS B.V.
- Status: approved
🇪🇺 Xcopri in European Union
EMA authorised Xcopri on 26 March 2021
Marketing authorisation
Xcopri in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in European Union
Frequently asked questions
Is Xcopri approved in European Union?
Yes. EMA authorised it on 26 March 2021.
Who is the marketing authorisation holder for Xcopri in European Union?
ARVELLE THERAPEUTICS NETHERLANDS B.V. holds the EU marketing authorisation.